Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

Next Previous
Trial Profile

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel; Temozolomide
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms BROCADE
  • Sponsors Abbott Laboratories; AbbVie; AbbVie Germany

Most Recent Events

  • 22 Oct 2020 Status changed from active, no longer recruiting to completed.
  • 18 Mar 2020 Planned End Date changed from 23 Jan 2020 to 24 Dec 2020.
  • 12 Nov 2019 Planned End Date changed from 28 Sep 2019 to 23 Jan 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top